Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability
- 1 October 2003
- journal article
- Published by Elsevier BV in Kidney International
- Vol. 64 (4), 1310-1319
- https://doi.org/10.1046/j.1523-1755.2003.00232.x
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Genetics and Pathogenesis of Polycystic Kidney DiseaseJournal of the American Society of Nephrology, 2002
- A novel inhibitor of tumor necrosis factor-α converting enzyme ameliorates polycystic kidney diseaseKidney International, 2001
- Treatment prospects for autosomal-dominant polycystic kidney diseaseKidney International, 2001
- Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injuryJCI Insight, 2000
- Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitorKidney International, 2000
- New insights into the molecular pathophysiology of polycystic kidney diseaseKidney International, 1999
- An Essential Role for Ectodomain Shedding in Mammalian DevelopmentScience, 1998
- Polycystic kidney disease: The complete structure of the PKD1 gene and its proteinCell, 1995
- Tyrosine kinase activity of the EGF receptor in murine metanephric organ cultureKidney International, 1995
- Epidermal growth factor receptor expression is abnormal in murine polycystic kidneyKidney International, 1995